Johnson & Johnson announced on October 23, 2026, that the European Commission approved TECVAYLI monotherapy for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The decision moves the standalone treatment into the second-line setting, expanding its use beyond the previous European indication requiring at least three prior therapies.
Key Takeaways
- The approval adds a standalone teclistamab option as early as first relapse.
- MajesTEC-9 showed lower risks of disease progression or death and death alone than the trial’s standard treatments.
- The updated label introduces monthly dosing from month seven, with earlier transitions possible for eligible patients.
Table of Contents
- TECVAYLI monotherapy expands second-line options
- Phase 3 evidence shows survival benefits
- Higher severe infection rates accompany efficacy gains
- Updated dosing schedule reduces treatment frequency
- Conclusion
TECVAYLI monotherapy expands second-line options
The indication extension covers teclistamab, marketed as TECVAYLI, used on its own. It follows the European Commission’s August 2026 approval of teclistamab combined with daratumumab for use as early as second line.
The distinction matters because physicians now have both monotherapy and combination approaches available after a patient’s first treatment. Multiple myeloma is a blood cancer involving plasma cells in the bone marrow; relapsed disease returns after treatment, while refractory disease does not respond adequately to treatment.
Teclistamab is a ready-to-use bispecific antibody given by subcutaneous injection. It binds to BCMA and CD3 targets to redirect T-cells against myeloma cells.
| Item | Details |
|---|---|
| 18-month progression-free survival | 69.8% with teclistamab versus 26.9% with comparator regimens. |
| 18-month overall survival | 79.2% with teclistamab versus 68.6% with comparator regimens. |
| Complete response or better | 65.9% with teclistamab versus 16.8% with comparator regimens. |
Phase 3 evidence shows survival benefits
The approval is supported by MajesTEC-9, an ongoing randomized Phase 3 study involving patients who had received one to three prior treatment lines, including lenalidomide and an anti-CD38 monoclonal antibody. The comparators were pomalidomide, bortezomib and dexamethasone, or carfilzomib and dexamethasone.
Johnson & Johnson’s May 2026 MajesTEC-9 results announcement detailed a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death with teclistamab versus those comparator regimens. These are relative risk reductions during the study, not the proportion of patients cured.
At 18 months, the trial also showed higher progression-free and overall survival rates, alongside a larger share of patients achieving a complete response or better.
Higher severe infection rates accompany efficacy gains
The company described the safety findings as consistent with teclistamab’s established profile. However, Grade 3 or 4 adverse events occurred in 84.9% of teclistamab recipients, compared with 76.3% receiving the comparator regimens. Grade 5, or fatal, adverse events occurred in 6.5% versus 3.5%; these figures do not by themselves establish treatment causation.
Grade 3 or 4 infections were more frequent with teclistamab, at 41.6% versus 29.0%. Rates of Grade 3 or higher infections declined over time. Median treatment duration was also longer with teclistamab: 13.1 months, compared with 7.0 months for standard care.
Updated dosing schedule reduces treatment frequency
The updated label will replace the existing monotherapy indication and dosing instructions. It introduces monthly dosing from month seven onward, while eligible patients may transition to monthly dosing as early as month three.
Less frequent administration could reduce treatment visits for eligible patients, although the announcement does not quantify that effect. Teclistamab remains subject to additional monitoring under European Medicines Agency requirements.
Conclusion
The approval broadens Johnson & Johnson’s European myeloma treatment offering at first relapse. MajesTEC-9 remains ongoing, making longer-term survival and safety follow-up the next evidence to watch; the announcement gives no date for another data update.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
